GlassScriptPhysician profile
Suellen Turner
NPI 1275758203
$2,818.74
in general payments reported to CMS, 2019-2025
34 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $517 · 2022: $251 · 2023: $976 · 2024: $562 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $529.90 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $243.14 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $219.81 | 2021-2025 | Airsupra, Farxiga |
| Abbvie INC. | $198.90 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.07 | 2021-2025 | Jardiance |
| Amgen INC. | $149.80 | 2021-2025 | Evenity, Prolia, Otezla |
| Insightec,INC | $147.06 | 2023-2024 | Exablate |
| Glaxosmithkline, LLC. | $140.90 | 2021-2025 | Shingrix, Arexvy |
| Pfizer INC. | $130.56 | 2021-2025 | |
| Dexcom, INC. | $118.25 | 2021-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $106.87 | 2021-2024 | Xarelto |
| Astellas Pharma US INC | $85.29 | 2023-2024 | Veozah |
| Alnylam Pharmaceuticals INC. | $73.19 | 2023 | Givlaari |
| Merck Sharp & Dohme LLC | $49.54 | 2021-2025 | Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $38.05 | 2023 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $31.30 | 2024 | Inspire |
| Daiichi Sankyo INC. | $28.64 | 2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $28.41 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.11 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.14 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $23.41 | 2025 | Uptravi, Opsumit |
| Axsome Therapeutics, INC. | $22.85 | 2025 | Auvelity |
| Edwards Lifesciences Corporation | $20.32 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Corium, LLC | $19.92 | 2023 | Adlarity |
| Bausch Health US, LLC | $19.31 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.04 | 2021 | |
| Antares Pharma, INC. | $17.99 | 2024 | Xyosted |
| Philips North America LLC | $17.45 | 2024 | (Ck6) Holter |
| Biohaven Pharmaceuticals, INC. | $17.05 | 2021 | |
| Amarin Pharma, INC. | $16.13 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.79 | 2025 | Unithroid |
| Otsuka America Pharmaceutical, INC. | $15.52 | 2022 | |
| Esperion Therapeutics, INC. | $14.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.33 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suellen Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.